The U.S. Food and Drug Administration (FDA) has a record for an injectable product containing Hydrocortisone Acetate. The product, marketed by Watson Labs, is identified as a 50 mg/mL injectable solution. It is listed under application number ANDA085214. The FDA entry indicates the product is discontinued and was not designated as a reference drug or reference standard. No further marketing status or approval details are provided beyond the discontinuation notice.
Actualités réglementaires10 sept. 2026•1 min de lecture
FDA Lists Discontinued Hydrocortisone Acetate Injection (ANDA085214)
The FDA record shows Watson Labs' injectable Hydrocortisone Acetate (50 mg/mL) has been discontinued under ANDA085214.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note